Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1035–47.

Article  CAS  PubMed  Google Scholar 

Global Cancer Observatory. International Agency for Research on Cancer. 2022. https://gco.iarc.fr/. Accessed 15 Feb 2023.

Ferlay J, Ervik M, Lam F, Colombet M, Mery L PM. Global cancer observatory: cancer today. [Internet]. International Agency for Research on Cancer (IARC). 2018. Available from: https://gco.iarc.fr/today. Accessed 15 Feb 2023.

Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1765–77.

Article  CAS  PubMed  Google Scholar 

Rueda Domínguez A, Cirauqui B, García Castaño A, Alvarez Cabellos R, Carral Maseda A, Castelo Fernández B, et al. SEOM-TTCC clinical guideline in nasopharynx cancer (2021). Clin Transl Oncol. 2022;24(4):670–80. https://doi.org/10.1007/s12094-022-02814-x.

Article  PubMed  PubMed Central  Google Scholar 

Stelow EB, Wenig BM. Update from the 4th edition of the World Health Organization classification of head and neck tumours: nasopharynx. Head Neck Pathol. 2017;11(1):16–22.

Article  PubMed  PubMed Central  Google Scholar 

Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387(10022):1012–24. https://doi.org/10.1016/S0140-6736(15)00055-0.

Article  PubMed  Google Scholar 

Dogan S, Hedberg ML, Ferris RL, Rath TJ, Assaad AM, Chiosea SI. Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population. Head Neck [Internet]. 2014;36(4):511–6. https://doi.org/10.1002/hed.2331.

Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, et al. Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(4):452–65. https://doi.org/10.1016/j.annonc.2020.12.007.

Article  CAS  PubMed  Google Scholar 

Lee VHF, Kwong DLW, Leung TW, Choi CW, O’Sullivan B, Lam KO, et al. The addition of pretreatment plasma Epstein-Barr virus DNA into the eighth edition of nasopharyngeal cancer TNM stage classification. Int J Cancer. 2019;144(7):1713–22.

Article  CAS  PubMed  Google Scholar 

Lee AWM, Ma BBY, Ng WT, Chan ATC. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol. 2015;33(29):3356–64.

Article  PubMed  Google Scholar 

Taylor A, Powell MEB. Intensity-modulated radiotherapy - what is it? Cancer Imaging. 2004;4(2):68–73.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee AWM, Ng WT, Chan LLK, Hung WM, Chan CCC, Sze HCK, et al. Evolution of treatment for nasopharyngeal cancer - success and setback in the intensity-modulated radiotherapy era. Radiother Oncol. 2014;110(3):377–84. https://doi.org/10.1016/j.radonc.2014.02.003.

Article  PubMed  Google Scholar 

Kam MKM, Leung SF, Zee B, Chau RMC, Suen JJS, Mo F, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol. 2007;25(31):4873–9.

Article  PubMed  Google Scholar 

Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J Clin Oncol. 2009;27(22):3684–90.

Article  PubMed  PubMed Central  Google Scholar 

Liu YP, Lv X, Zou X, Hua YJ, You R, Yang Q, et al. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage i nasopharyngeal carcinoma. Cancer Commun. 2019;39(1):1–11. https://doi.org/10.1186/s40880-019-0415-3.

Article  Google Scholar 

Li JG, Yuan X, Zhang LL, Tang YQ, Liu L, Chen XD, et al. A randomized clinical trial comparing prophylactic upper versus whole-neck irradiation in the treatment of patients with node-negative nasopharyngeal carcinoma. Cancer. 2013;119(17):3170–6.

Article  PubMed  Google Scholar 

Wu F, Wang R, Lu H, Wei B, Feng G, Li G, et al. Concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: treatment outcomes of a prospective multicentric clinical study. Radiother Oncol. 2014;112(1):106–11. https://doi.org/10.1016/j.radonc.2014.05.005.

Article  PubMed  Google Scholar 

Yi J, Huang X, Gao L, Luo J, Zhang S, Wang K, et al. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma. Radiat Oncol. 2014;9(1):2–8.

Article  Google Scholar 

Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol [Internet]. 1998;16(4):1310–7. https://doi.org/10.1200/JCO.1998.16.4.1310.

Wu X, Huang PY, Peng PJ, Lu LX, Han F, Wu SX, et al. Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2013;24(8):2131–6.

Article  CAS  PubMed  Google Scholar 

Lee AWM, Tung SY, Chua DTT, Ngan RKC, Chappell R, Tung R, et al. Randomized trial of radiotherapy plus concurrent-adjuvant chemotherapy vs radiotherapy alone for regionally advanced nasopharyngeal carcinoma. J Natl Cancer Inst. 2010;102(15):1188–98.

Article  PubMed  Google Scholar 

Zhang L, Zhao C, Peng PJ, Lu LX, Huang PY, Han F, et al. Phase III study comparing standard radiotherapy with or without weekly oxaliplatin in treatment of locoregionally advanced nasopharyngeal carcinoma: Preliminary results. J Clin Oncol. 2005;23(33):8461–8.

Article  CAS  PubMed  Google Scholar 

Blanchard P, Lee AWM, Carmel A, Wai Tong N, Ma J, Chan ATC, et al. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): an update on 26 trials and 7080 patients. Clin Transl Radiat Oncol. 2021;2022(32):59–68.

Google Scholar 

Zhang L, Zhao C, Ghimire B, Hong MH, Liu Q, Zhang Y, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase iii randomized trials. BMC Cancer. 2010;10(1):558. https://doi.org/10.1186/1471-2407-10-558.

He Y, Guo T, Guan H, Wang J, Sun Y, Peng X. Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma in the era of intensitymodulated radiotherapy: a meta-analysis. Cancer Manag Res. 2018;10:1419–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015;16(6):645–55. https://doi.org/10.1016/S1470-2045(15)70126-9.

Article  PubMed  Google Scholar 

Hui EP, Ma BBY, Chan ATC. The emerging data on choice of optimal therapy for locally advanced nasopharyngeal carcinoma. Curr Opin Oncol. 2020;32(3):187–95.

Article  PubMed  Google Scholar 

Ma BBY, Chen Y-P, Hui EP, Liu X, Chan AKC, Chan ATC, et al. Recent advances in the development of biomarkers and chemoradiotherapeutic approaches for nasopharyngeal carcinoma. Am Soc Clin Oncol Educ B. 2020;40:270–80.

Article  Google Scholar 

Wee J, Tan EH, Tai BC, Wong HB, Leong SS, Tan T, et al. Randomized trial of radiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in patients with American Joint Committee on Cancer/International Union Against Cancer stage III and IV nasopharyngeal cancer of the endemic variety. J Clin Oncol. 2005;23(27):6730–8.

Article  CAS  PubMed  Google Scholar 

Lee AWM, Tung SY, Chan ATC, Chappell R, Fu YT, Lu TX, et al. A randomized trial on addition of concurrent-adjuvant chemotherapy and/or accelerated fractionation for locally-advanced nasopharyngeal carcinoma. Radiother Oncol. 2011;98(1):15–22. https://doi.org/10.1016/j.radonc.2010.09.023.

Article  PubMed  Google Scholar 

Chen Y, Sun Y, Liang SB, Zong JF, Li WF, Chen M, et al. Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of Ch. Cancer. 2013;119(12):2230–8.

Article  CAS  PubMed  Google Scholar 

Lee AWM, Tung SY, Ng WT, Lee V, Ngan RKC, Choi HCW, et al. A multicenter, phase 3, randomized trial of concurrent chemoradiotherapy plus adjuvant chemotherapy versus radiotherapy alone in patients with regionally advanced nasopharyngeal carcinoma: 10-year outcomes for efficacy and toxicity. Cancer. 2017;123(21):4147–57.

Article  CAS  PubMed  Google Scholar 

Twu CW, Wang WY, Chen CC, Liang KL, Jiang RS, Te WuC, et al. Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid. Int J Radiat Oncol Biol Phys. 2014;89(1):21–9. https://doi.org/10.1016/j.ijrobp.2014.01.052.

Article  PubMed  Google Scholar 

Rossi A, Molinari R, Boracchi P, Del Vecchio M, Marubini E, Nava M, et al. Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. J Clin Oncol. 1988;6(9):1401–10.

Article  CAS  PubMed  Google Scholar 

Chi KH, Chang YC, Guo WY, Leung MJ, Shiau CY, Chen SY, et al. A phase III study of adjuvant chemotherapy in advanced nasopharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys. 2002;52(5):1238–44.

Article  CAS  PubMed  Google Scholar 

Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, et al. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase 3 multicentre randomised controlled trial. Eur J Cancer. 2017;75(January):150–8. https://doi.org/10.1016/j.ejca.2017.01.002.

Article  CAS  PubMed  Google Scholar 

Fang L, Shi L, Wang W, Hu T, Rao X. Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials. Eur Arch Oto-Rhino-Laryngol. 2021;278(10):3633–42. https://doi.org/10.1007/s00405-021-06614-x.

Article  Google Scholar 

Hui EP, Ma BB, Leung SF, King AD, Mo F, Kam MK, et al. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol. 2009;27(2):242–9.

Article  CAS  PubMed  Google Scholar 

Zhang Y, Chen L, Hu G-Q, Zhang N, Zhu X-D, Yang K-Y, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124–35.

Article  CAS